April 4th 2023

Amicoat has signed the first commercial contract with an undisclosed partner. Amicoat will support the integration of the patented antimicrobial peptide voxvoganan into a product manufactured by the partner. The goal is to provide an antimicrobial effect and limit bacterial growth on the medical device to reduce the rate of associated infections.